Why the study?
Does ximelagatran reduce thromboembolic risk in patients with non-valvular atrial fibrillation?
Does ximelagatran reduce thromboembolic risk in patients with non-valvular atrial fibrillation?
Answers are grounded in this paper and cite their sources.
This review discusses the emergence of ximelagatran, a direct thrombin inhibitor, as a novel option for thromboprophylaxis in non-valvular atrial fibrillation.
Antithrombotic agents have verified efficacy in reducing the thromboembolic risk associated with atrial fibrillation. This article focuses on the emergence of a new oral direct thrombin inhibitor, ximelagatran, into the arena of atrial fibrillation thromboprophylaxis. This review does not cover atrial fibrillation in the context of valvular heart disease. The efficacy of aspirin and warfarin will be discussed briefly.
No takes yet. Share an insight, caveat, or question.
Katira et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: